Transcode Therapeutics, Inc. Logo

Transcode Therapeutics, Inc.

Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.

RNAZ | US

Overview

Corporate Details

ISIN(s):
US89357L1052
LEI:
Country:
United States of America
Address:
6 LIBERTY SQUARE, 2109 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Transcode Therapeutics, Inc. is a clinical-stage oncology company focused on developing targeted therapies for metastatic disease. The company's lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b, a key regulator of metastasis. Transcode utilizes its proprietary TTX drug delivery platform, which employs tunable iron oxide nanoparticles to deliver RNA-based therapeutics specifically to cancer cells, addressing a significant challenge in the field. This platform technology has demonstrated broad potential in pre-clinical models across numerous cancer types, including breast, pancreatic, and ovarian cancer. The company aims to eradicate metastatic tumor cells that have spread from the primary tumor. Transcode recently acquired Polynoma LLC to enhance its immuno-oncology and metastatic prevention capabilities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Transcode Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Transcode Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Transcode Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Whitehawk Therapeutics, Inc. Logo
Develops advanced antibody-drug conjugates (ADCs) for difficult-to-treat cancers.
United States of America
WHWK
WooGeneB&GCO.,Ltd Logo
Manufactures veterinary medicines, vaccines, and supplements for livestock and aquatic animals.
South Korea
018620
X4 Pharmaceuticals, Inc Logo
Developing and commercializing novel therapies for rare diseases of the immune system.
United States of America
XFOR
XBiotech Inc. Logo
Develops therapeutic antibodies from natural human immunity for inflammatory diseases and oncology.
United States of America
XBIT
Xbrane Biopharma Logo
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
Sweden
XBRANE
Xencor Inc Logo
Engineering antibody & cytokine therapeutics for cancer and autoimmune diseases via its XmAb platform.
United States of America
XNCR
Xenon Pharmaceuticals Inc. Logo
A neuroscience biopharma developing novel therapeutics for epilepsy and depression.
United States of America
XENE
Xeris Biopharma Holdings, Inc. Logo
Develops ready-to-use injectable drugs for chronic, metabolic, and rare diseases.
United States of America
XERS
Xintela AB Logo
Develops stem cell therapies for osteoarthritis and venous leg ulcers using proprietary technology.
Sweden
XINT
Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden
XSPRAY

Talk to a Data Expert

Have a question? We'll get back to you promptly.